 Dara Aisner
Concepts (409)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 62 | 2023 | 2222 | 4.960 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 41 | 2023 | 975 | 3.570 |
Why?
| | Genetic Testing | 9 | 2022 | 379 | 2.440 |
Why?
| | Pathology, Molecular | 7 | 2019 | 26 | 2.120 |
Why?
| | ErbB Receptors | 19 | 2023 | 561 | 2.100 |
Why?
| | Oncogene Proteins, Fusion | 13 | 2019 | 179 | 2.030 |
Why?
| | Mutation | 38 | 2023 | 3353 | 1.990 |
Why?
| | High-Throughput Nucleotide Sequencing | 14 | 2023 | 441 | 1.920 |
Why?
| | Protein Kinase Inhibitors | 24 | 2023 | 796 | 1.720 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2020 | 92 | 1.660 |
Why?
| | Neoplasms | 12 | 2023 | 2106 | 1.540 |
Why?
| | Proto-Oncogene Proteins B-raf | 13 | 2022 | 193 | 1.490 |
Why?
| | Proto-Oncogene Proteins | 17 | 2018 | 611 | 1.440 |
Why?
| | Protein-Tyrosine Kinases | 12 | 2018 | 399 | 1.390 |
Why?
| | Biomarkers, Tumor | 17 | 2023 | 1054 | 1.240 |
Why?
| | Receptor Protein-Tyrosine Kinases | 10 | 2019 | 227 | 1.130 |
Why?
| | DNA, Neoplasm | 3 | 2019 | 157 | 1.120 |
Why?
| | Antineoplastic Agents | 15 | 2019 | 1897 | 1.120 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 11 | 2020 | 229 | 1.090 |
Why?
| | Drug Resistance, Neoplasm | 13 | 2023 | 642 | 1.030 |
Why?
| | Proto-Oncogene Proteins c-met | 5 | 2019 | 69 | 0.980 |
Why?
| | Colorectal Neoplasms | 3 | 2022 | 621 | 0.910 |
Why?
| | Gene Rearrangement | 13 | 2019 | 138 | 0.860 |
Why?
| | Adenocarcinoma | 9 | 2018 | 801 | 0.860 |
Why?
| | Brain Neoplasms | 10 | 2018 | 987 | 0.840 |
Why?
| | Ganglioglioma | 4 | 2014 | 31 | 0.770 |
Why?
| | Molecular Targeted Therapy | 10 | 2018 | 347 | 0.750 |
Why?
| | DNA Mutational Analysis | 11 | 2020 | 372 | 0.740 |
Why?
| | Precision Medicine | 4 | 2018 | 339 | 0.720 |
Why?
| | Humans | 116 | 2023 | 114925 | 0.700 |
Why?
| | Pyrazoles | 10 | 2018 | 364 | 0.690 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 61 | 0.680 |
Why?
| | Biological Products | 1 | 2022 | 169 | 0.670 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2020 | 88 | 0.670 |
Why?
| | Immunohistochemistry | 10 | 2023 | 1635 | 0.660 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 5 | 0.660 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 15 | 0.660 |
Why?
| | Prognosis | 13 | 2023 | 3344 | 0.650 |
Why?
| | Astrocytoma | 3 | 2015 | 109 | 0.650 |
Why?
| | Insurance Coverage | 1 | 2020 | 202 | 0.630 |
Why?
| | Neoplasm Metastasis | 9 | 2022 | 530 | 0.610 |
Why?
| | Computational Biology | 4 | 2023 | 531 | 0.600 |
Why?
| | In Situ Hybridization, Fluorescence | 13 | 2019 | 314 | 0.590 |
Why?
| | Laboratory Proficiency Testing | 2 | 2023 | 7 | 0.590 |
Why?
| | RNA | 5 | 2019 | 810 | 0.540 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2023 | 447 | 0.520 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2016 | 82 | 0.480 |
Why?
| | Smoking | 3 | 2018 | 1391 | 0.470 |
Why?
| | ras Proteins | 5 | 2015 | 138 | 0.460 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 863 | 0.460 |
Why?
| | Pyridines | 8 | 2016 | 425 | 0.450 |
Why?
| | Aged, 80 and over | 16 | 2023 | 6363 | 0.430 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 1361 | 0.420 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 175 | 0.420 |
Why?
| | Neoplasm Staging | 11 | 2018 | 1180 | 0.400 |
Why?
| | Female | 49 | 2023 | 59571 | 0.390 |
Why?
| | Telomerase | 7 | 2002 | 206 | 0.380 |
Why?
| | Male | 48 | 2022 | 55655 | 0.380 |
Why?
| | Aged | 28 | 2023 | 19120 | 0.380 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 359 | 0.380 |
Why?
| | S100 Proteins | 2 | 2014 | 38 | 0.370 |
Why?
| | Genomics | 4 | 2023 | 641 | 0.360 |
Why?
| | Middle Aged | 36 | 2023 | 26801 | 0.360 |
Why?
| | Early Detection of Cancer | 2 | 2019 | 339 | 0.340 |
Why?
| | Curriculum | 1 | 2016 | 845 | 0.340 |
Why?
| | Sulfones | 3 | 2015 | 97 | 0.330 |
Why?
| | Glycine | 3 | 2015 | 152 | 0.330 |
Why?
| | Pyrimidines | 3 | 2018 | 378 | 0.330 |
Why?
| | Laboratories | 2 | 2023 | 95 | 0.320 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 436 | 0.310 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2022 | 81 | 0.300 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2022 | 52 | 0.290 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 77 | 0.280 |
Why?
| | Adult | 31 | 2023 | 30604 | 0.280 |
Why?
| | Oncogene Fusion | 2 | 2019 | 9 | 0.280 |
Why?
| | Melanoma | 2 | 2020 | 631 | 0.280 |
Why?
| | Exons | 5 | 2019 | 302 | 0.280 |
Why?
| | Treatment Outcome | 11 | 2019 | 9105 | 0.280 |
Why?
| | Gene Dosage | 2 | 2018 | 134 | 0.280 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 51 | 0.280 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 152 | 0.270 |
Why?
| | Genetic Predisposition to Disease | 6 | 2019 | 2102 | 0.270 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2023 | 330 | 0.260 |
Why?
| | Oncogenes | 3 | 2016 | 108 | 0.260 |
Why?
| | Immunotherapy | 5 | 2022 | 475 | 0.250 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIb | 3 | 2015 | 9 | 0.250 |
Why?
| | Receptor, ErbB-2 | 4 | 2022 | 301 | 0.250 |
Why?
| | Epithelioid Cells | 2 | 2015 | 8 | 0.240 |
Why?
| | Sensitivity and Specificity | 5 | 2019 | 1700 | 0.230 |
Why?
| | Cell Line, Tumor | 11 | 2018 | 2725 | 0.220 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 10 | 0.220 |
Why?
| | Survival Analysis | 4 | 2021 | 1220 | 0.220 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 584 | 0.220 |
Why?
| | Mesothelioma | 1 | 2023 | 31 | 0.220 |
Why?
| | Endodermal Sinus Tumor | 1 | 2022 | 7 | 0.210 |
Why?
| | Choriocarcinoma | 1 | 2022 | 8 | 0.210 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 126 | 0.210 |
Why?
| | Pathologists | 2 | 2023 | 15 | 0.210 |
Why?
| | Young Adult | 12 | 2019 | 10476 | 0.200 |
Why?
| | Goals | 1 | 2023 | 151 | 0.200 |
Why?
| | Patient Selection | 4 | 2018 | 642 | 0.200 |
Why?
| | Cell Proliferation | 7 | 2017 | 2199 | 0.200 |
Why?
| | Biopsy, Fine-Needle | 2 | 2012 | 64 | 0.200 |
Why?
| | Endometrial Neoplasms | 1 | 2023 | 141 | 0.200 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 136 | 0.200 |
Why?
| | Gene Fusion | 2 | 2018 | 18 | 0.200 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 62 | 0.190 |
Why?
| | Glioblastoma | 2 | 2015 | 253 | 0.190 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 30 | 0.190 |
Why?
| | Graft vs Host Disease | 1 | 2023 | 215 | 0.190 |
Why?
| | Combined Modality Therapy | 4 | 2018 | 1126 | 0.190 |
Why?
| | Biopsy | 4 | 2018 | 1045 | 0.190 |
Why?
| | Pheochromocytoma | 1 | 2022 | 54 | 0.190 |
Why?
| | United States | 9 | 2020 | 12209 | 0.190 |
Why?
| | Trastuzumab | 1 | 2021 | 89 | 0.190 |
Why?
| | Carbazoles | 1 | 2021 | 78 | 0.180 |
Why?
| | Meningioma | 1 | 2022 | 78 | 0.180 |
Why?
| | Neoadjuvant Therapy | 2 | 2023 | 305 | 0.180 |
Why?
| | Laboratories, Hospital | 1 | 2020 | 13 | 0.180 |
Why?
| | Pathology, Clinical | 2 | 2017 | 32 | 0.180 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 66 | 0.170 |
Why?
| | Government Regulation | 1 | 2020 | 46 | 0.170 |
Why?
| | Piperidines | 1 | 2021 | 162 | 0.170 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 195 | 0.170 |
Why?
| | Stakeholder Participation | 1 | 2020 | 73 | 0.170 |
Why?
| | Chromosome Aberrations | 2 | 2019 | 138 | 0.170 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 312 | 0.170 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2017 | 52 | 0.160 |
Why?
| | Genes, erbB-2 | 2 | 2015 | 26 | 0.160 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 45 | 0.160 |
Why?
| | Pregnancy Complications | 1 | 2023 | 430 | 0.160 |
Why?
| | Smad4 Protein | 1 | 2019 | 34 | 0.160 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 49 | 0.160 |
Why?
| | Acrylamides | 2 | 2017 | 42 | 0.160 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 29 | 0.160 |
Why?
| | Multigene Family | 1 | 2019 | 193 | 0.160 |
Why?
| | Pyridazines | 1 | 2018 | 49 | 0.150 |
Why?
| | Genetic Markers | 1 | 2019 | 322 | 0.150 |
Why?
| | Cell Cycle Proteins | 4 | 2015 | 552 | 0.150 |
Why?
| | Piperazines | 2 | 2018 | 313 | 0.150 |
Why?
| | Database Management Systems | 1 | 2018 | 48 | 0.150 |
Why?
| | Thromboembolism | 1 | 2018 | 94 | 0.150 |
Why?
| | Ovarian Neoplasms | 1 | 2022 | 388 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2018 | 195 | 0.150 |
Why?
| | Gene Frequency | 1 | 2019 | 481 | 0.150 |
Why?
| | Genetic Association Studies | 1 | 2019 | 345 | 0.150 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2018 | 28 | 0.150 |
Why?
| | Skin Neoplasms | 2 | 2020 | 762 | 0.150 |
Why?
| | Quinazolines | 3 | 2014 | 243 | 0.150 |
Why?
| | Smokers | 1 | 2018 | 129 | 0.150 |
Why?
| | Indoles | 2 | 2017 | 306 | 0.140 |
Why?
| | Imidazoles | 1 | 2018 | 211 | 0.140 |
Why?
| | Intraoperative Care | 1 | 2017 | 34 | 0.140 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 125 | 0.140 |
Why?
| | Gene Deletion | 1 | 2019 | 356 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 142 | 0.140 |
Why?
| | Medical Informatics | 1 | 2018 | 92 | 0.140 |
Why?
| | Chloroquine | 1 | 2017 | 52 | 0.140 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 268 | 0.140 |
Why?
| | Coculture Techniques | 1 | 2017 | 201 | 0.140 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 80 | 0.140 |
Why?
| | RNA, Messenger | 4 | 2018 | 2558 | 0.130 |
Why?
| | Sulfonamides | 2 | 2017 | 445 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2017 | 179 | 0.130 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 14 | 0.130 |
Why?
| | Liver Neoplasms | 3 | 2015 | 509 | 0.130 |
Why?
| | Pleural Neoplasms | 1 | 2016 | 18 | 0.130 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 158 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2016 | 63 | 0.130 |
Why?
| | Signal Transduction | 5 | 2017 | 4524 | 0.130 |
Why?
| | Immunity, Humoral | 1 | 2016 | 112 | 0.130 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 54 | 0.130 |
Why?
| | Codon | 1 | 2016 | 86 | 0.130 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2016 | 59 | 0.130 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2016 | 66 | 0.130 |
Why?
| | Medical Oncology | 3 | 2023 | 228 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1400 | 0.130 |
Why?
| | Protein Kinases | 1 | 2017 | 307 | 0.120 |
Why?
| | Oncogene Proteins | 1 | 2015 | 53 | 0.120 |
Why?
| | Clinical Laboratory Techniques | 1 | 2016 | 87 | 0.120 |
Why?
| | Fatal Outcome | 1 | 2016 | 285 | 0.120 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 262 | 0.120 |
Why?
| | Medicare | 1 | 2020 | 666 | 0.120 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 390 | 0.120 |
Why?
| | Immunity, Cellular | 1 | 2016 | 249 | 0.120 |
Why?
| | Hamartoma | 1 | 2015 | 21 | 0.120 |
Why?
| | Genetic Variation | 1 | 2019 | 876 | 0.120 |
Why?
| | Pharmacogenetics | 1 | 2016 | 149 | 0.120 |
Why?
| | Autophagy | 1 | 2017 | 234 | 0.120 |
Why?
| | Deoxycytidine | 1 | 2015 | 138 | 0.120 |
Why?
| | DNA Copy Number Variations | 4 | 2018 | 159 | 0.120 |
Why?
| | Meningeal Carcinomatosis | 1 | 2014 | 8 | 0.120 |
Why?
| | Lung Transplantation | 1 | 2016 | 246 | 0.120 |
Why?
| | Alternative Splicing | 3 | 2017 | 187 | 0.120 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 38 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2020 | 1022 | 0.120 |
Why?
| | Multimodal Imaging | 1 | 2015 | 92 | 0.120 |
Why?
| | Health Care Surveys | 1 | 2016 | 539 | 0.120 |
Why?
| | Speech Disorders | 1 | 2014 | 30 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2015 | 278 | 0.110 |
Why?
| | Paresis | 1 | 2014 | 28 | 0.110 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 995 | 0.110 |
Why?
| | Retrospective Studies | 9 | 2019 | 12543 | 0.110 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 147 | 0.110 |
Why?
| | Tumor Cells, Cultured | 5 | 2019 | 855 | 0.110 |
Why?
| | Receptor, trkA | 1 | 2013 | 16 | 0.110 |
Why?
| | Sarcoma | 1 | 2015 | 138 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2021 | 1856 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1148 | 0.110 |
Why?
| | Microscopy, Electron | 1 | 2014 | 410 | 0.110 |
Why?
| | Intracranial Hemorrhages | 1 | 2014 | 76 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 265 | 0.110 |
Why?
| | Graft Rejection | 1 | 2016 | 516 | 0.110 |
Why?
| | Serine Endopeptidases | 1 | 2013 | 102 | 0.110 |
Why?
| | Societies, Medical | 4 | 2018 | 677 | 0.110 |
Why?
| | Headache | 1 | 2014 | 132 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2015 | 194 | 0.110 |
Why?
| | Brain Stem Neoplasms | 1 | 2013 | 86 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 929 | 0.100 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 174 | 0.100 |
Why?
| | Disease Progression | 5 | 2018 | 2392 | 0.100 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 1801 | 0.100 |
Why?
| | Tissue Fixation | 1 | 2012 | 27 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 2 | 2013 | 617 | 0.100 |
Why?
| | Lung | 4 | 2015 | 3593 | 0.100 |
Why?
| | Gene Amplification | 3 | 2019 | 97 | 0.100 |
Why?
| | Algorithms | 1 | 2019 | 1474 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 374 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2326 | 0.100 |
Why?
| | Mutation Rate | 1 | 2011 | 26 | 0.100 |
Why?
| | Translocation, Genetic | 1 | 2012 | 94 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2017 | 958 | 0.090 |
Why?
| | Specimen Handling | 1 | 2012 | 156 | 0.090 |
Why?
| | Prospective Studies | 2 | 2023 | 6218 | 0.090 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 185 | 0.090 |
Why?
| | Teratoma | 1 | 2011 | 92 | 0.090 |
Why?
| | DNA-Binding Proteins | 6 | 2011 | 1317 | 0.090 |
Why?
| | Rhabdoid Tumor | 1 | 2011 | 80 | 0.090 |
Why?
| | Terminology as Topic | 1 | 2012 | 187 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2022 | 1870 | 0.090 |
Why?
| | Genome, Human | 1 | 2012 | 352 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 706 | 0.090 |
Why?
| | Survival Rate | 4 | 2019 | 1644 | 0.090 |
Why?
| | Phosphorylation | 1 | 2014 | 1572 | 0.080 |
Why?
| | Catheter Ablation | 1 | 2012 | 291 | 0.080 |
Why?
| | Immunoenzyme Techniques | 3 | 2015 | 195 | 0.080 |
Why?
| | Erlotinib Hydrochloride | 3 | 2014 | 65 | 0.080 |
Why?
| | Telomere | 3 | 2000 | 202 | 0.080 |
Why?
| | Disease-Free Survival | 3 | 2016 | 623 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2021 | 4427 | 0.080 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 733 | 0.080 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2008 | 13 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1355 | 0.080 |
Why?
| | beta Catenin | 2 | 2023 | 220 | 0.080 |
Why?
| | Adolescent | 6 | 2019 | 17826 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2018 | 25 | 0.080 |
Why?
| | Maximum Tolerated Dose | 2 | 2021 | 184 | 0.070 |
Why?
| | Heart Neoplasms | 1 | 2008 | 49 | 0.070 |
Why?
| | DNA | 1 | 2014 | 1351 | 0.070 |
Why?
| | Reproducibility of Results | 3 | 2019 | 2769 | 0.070 |
Why?
| | Internship and Residency | 1 | 2016 | 944 | 0.070 |
Why?
| | Workflow | 2 | 2017 | 135 | 0.070 |
Why?
| | Mental Disorders | 1 | 2014 | 891 | 0.070 |
Why?
| | Eye Neoplasms | 1 | 2005 | 16 | 0.060 |
Why?
| | Immunophenotyping | 1 | 2005 | 277 | 0.060 |
Why?
| | Administration, Oral | 2 | 2018 | 731 | 0.060 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2023 | 31 | 0.060 |
Why?
| | DNA Polymerase II | 1 | 2023 | 37 | 0.060 |
Why?
| | Peritoneum | 1 | 2023 | 36 | 0.060 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 37 | 0.060 |
Why?
| | Genes, ras | 2 | 2015 | 91 | 0.060 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 316 | 0.060 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 2 | 2013 | 33 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3053 | 0.050 |
Why?
| | Blotting, Western | 4 | 2015 | 1151 | 0.050 |
Why?
| | Cell Cycle | 2 | 2012 | 544 | 0.050 |
Why?
| | Carcinoma, Endometrioid | 1 | 2022 | 46 | 0.050 |
Why?
| | Cell Survival | 2 | 2017 | 1022 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 934 | 0.050 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2002 | 110 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2013 | 353 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1523 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 271 | 0.050 |
Why?
| | Models, Molecular | 2 | 2018 | 1379 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 434 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 62 | 0.040 |
Why?
| | Base Sequence | 3 | 2017 | 2118 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2002 | 399 | 0.040 |
Why?
| | Time Factors | 3 | 2020 | 6125 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 701 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2002 | 554 | 0.040 |
Why?
| | Catalytic Domain | 4 | 2000 | 197 | 0.040 |
Why?
| | Cohort Studies | 2 | 2019 | 4903 | 0.040 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 1999 | 43 | 0.040 |
Why?
| | Sequence Deletion | 2 | 2014 | 168 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 30 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2018 | 52 | 0.040 |
Why?
| | Cell Line | 4 | 2012 | 2640 | 0.040 |
Why?
| | Child | 5 | 2015 | 18362 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2023 | 525 | 0.040 |
Why?
| | Nausea | 1 | 2018 | 104 | 0.040 |
Why?
| | Proto-Oncogenes | 1 | 2018 | 26 | 0.040 |
Why?
| | RNA, Untranslated | 1 | 1999 | 113 | 0.040 |
Why?
| | Phthalazines | 1 | 2018 | 38 | 0.040 |
Why?
| | Cetuximab | 1 | 2018 | 91 | 0.040 |
Why?
| | Breast | 1 | 2018 | 141 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2017 | 21 | 0.040 |
Why?
| | Diarrhea | 1 | 2018 | 173 | 0.040 |
Why?
| | Quality Control | 1 | 2017 | 144 | 0.040 |
Why?
| | A549 Cells | 1 | 2017 | 51 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 503 | 0.030 |
Why?
| | Pathology, Surgical | 1 | 2016 | 7 | 0.030 |
Why?
| | Aniline Compounds | 1 | 2017 | 71 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2013 | 2791 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 296 | 0.030 |
Why?
| | Child, Preschool | 3 | 2015 | 9083 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 316 | 0.030 |
Why?
| | Centrosome | 1 | 2016 | 60 | 0.030 |
Why?
| | Carcinoma | 2 | 2012 | 199 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2002 | 1317 | 0.030 |
Why?
| | Dual Specificity Phosphatase 6 | 1 | 2015 | 5 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 534 | 0.030 |
Why?
| | Mice, Nude | 1 | 2017 | 635 | 0.030 |
Why?
| | Genes, erbB-1 | 1 | 2015 | 17 | 0.030 |
Why?
| | Lamin Type A | 1 | 2015 | 40 | 0.030 |
Why?
| | Cell Line, Transformed | 3 | 2000 | 133 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 113 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1440 | 0.030 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2015 | 66 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 82 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 591 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2017 | 251 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 729 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 666 | 0.030 |
Why?
| | Animals | 5 | 2019 | 31837 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 937 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 121 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 165 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 350 | 0.030 |
Why?
| | Microdissection | 1 | 2013 | 15 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 163 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 718 | 0.030 |
Why?
| | Disease Management | 1 | 2017 | 563 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1215 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 400 | 0.030 |
Why?
| | Transcriptome | 1 | 2018 | 728 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2013 | 102 | 0.030 |
Why?
| | Syndecan-4 | 1 | 2012 | 7 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2015 | 383 | 0.030 |
Why?
| | Incidence | 1 | 2018 | 2316 | 0.020 |
Why?
| | Bone and Bones | 1 | 2015 | 278 | 0.020 |
Why?
| | SMARCB1 Protein | 1 | 2011 | 17 | 0.020 |
Why?
| | Mice | 2 | 2019 | 14935 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2015 | 292 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 5525 | 0.020 |
Why?
| | Infant | 2 | 2015 | 7936 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2011 | 100 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 281 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 373 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 369 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 752 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1059 | 0.020 |
Why?
| | Bronchoscopy | 1 | 2012 | 246 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2014 | 476 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 262 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 1893 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1721 | 0.020 |
Why?
| | Retroviridae | 2 | 2000 | 90 | 0.020 |
Why?
| | Reticulocytes | 2 | 1999 | 16 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 797 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 3897 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2382 | 0.020 |
Why?
| | Genetic Vectors | 2 | 2000 | 291 | 0.020 |
Why?
| | Leukemic Infiltration | 1 | 2008 | 5 | 0.020 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2008 | 23 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1749 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 514 | 0.020 |
Why?
| | Rabbits | 2 | 1999 | 748 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2008 | 106 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1999 | 1034 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 2817 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3418 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2371 | 0.020 |
Why?
| | Fibroblasts | 2 | 2000 | 839 | 0.020 |
Why?
| | Transcription Factors | 1 | 2011 | 1530 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2013 | 5035 | 0.010 |
Why?
| | Peptide Chain Termination, Translational | 1 | 2000 | 5 | 0.010 |
Why?
| | Fetal Proteins | 1 | 2000 | 16 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2000 | 94 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 2000 | 39 | 0.010 |
Why?
| | Fibrosarcoma | 1 | 2000 | 20 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 257 | 0.010 |
Why?
| | Protein Subunits | 1 | 2000 | 201 | 0.010 |
Why?
| | Quinones | 1 | 1999 | 10 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1999 | 34 | 0.010 |
Why?
| | Lactams, Macrocyclic | 1 | 1999 | 46 | 0.010 |
Why?
| | Benzoquinones | 1 | 1999 | 44 | 0.010 |
Why?
| | Cyclosporine | 1 | 1999 | 161 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 870 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2000 | 173 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 1999 | 157 | 0.010 |
Why?
| | Half-Life | 1 | 1997 | 141 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 385 | 0.010 |
Why?
| | RNA, Long Noncoding | 1 | 1999 | 154 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 1999 | 431 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1999 | 1233 | 0.010 |
Why?
| | Skin | 1 | 2000 | 659 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1997 | 1087 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2000 | 925 | 0.010 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|